Opiant Pharmaceuticals Announces Third Quarter 2020 Financial Results and Corporate Update

Opiant to use Aptar Pharma’s Unit Dose System - Upcoming FDA meeting in December to review Pharmacodynamic study in healthy volunteers and 505 (b) (2) submission strategy - Opiant continues to expect to file a New Drug Application by end of 2021 - The Centers for Disease Control and Prevention reports an increase in fatal drug overdoses in the first three months of 2020 putting the U.